Literature DB >> 23550693

Decreased peripheral blood CD4+/CD25+ regulatory T cells in patients with alcoholic hepatitis.

Julia Almeida1, Maria Angeles Polvorosa, Arturo Gonzalez-Quintela, Miguel Marcos, Isabel Pastor, Maria Luisa Hernandez Cerceño, Alberto Orfao, Francisco-Javier Laso.   

Abstract

BACKGROUND: Development of alcoholic hepatitis (AH) may be favored by the activation of the innate immune response. Recently, decreased numbers of circulating regulatory T cells (Tregs) have been reported in diseases associated with an immune activation status, but no studies have focused so far, in investigating the distribution of Tregs in chronic alcoholism and its potential association with liver disease. Here, we analyzed for the first time the frequency of peripheral blood (PB) Tregs and Treg subsets in AH and its relationship with the production of inflammatory cytokines by PB monocytes and dendritic cells (DCs).
METHODS: PB samples from 25 male patients with AH were studied; in parallel, 15 male chronic alcoholic patients without liver disease (AWLD) and 17 male healthy donors were also studied, as controls. The distribution of CD4⁺CD25hiCD127-/lo Tregs and their maturation subsets (naïve, central memory, and peripheral memory Tregs) was analyzed by flow cytometry. Spontaneous and in vitro-stimulated production of inflammatory cytokines by PB monocytes and DCs was analyzed by flow cytometry at the cytoplasmic level.
RESULTS: Patients with AH showed decreased (p < 0.05) numbers of PB CD4⁺CD25hiCD127-/lo Tregs at the expense of all maturation-associated subsets, while AWLD and healthy subjects showed a similar (p > 0.05) distribution of PB CD4⁺CD25hiCD127-/lo Tregs. Interestingly, significantly increased amounts of spontaneously produced inflammatory cytokines were found among circulating monocyte-derived DCs and monocytes from AH (and AWLD) patients in comparison with healthy donors. Conversely, the ability of these cell subsets to produce cytokines after in vitro stimulation was lower (p < 0.05) in AH versus the 2 control groups.
CONCLUSIONS: PB CD4⁺CD25hiCD127-/lo Tregs are significantly decreased in patients with AH when compared to both healthy and AWLD; this may contribute to explain the more pronounced activation of the innate immune response observed in AH, as reflected by an increased secretion of inflammatory cytokines by PB DCs and monocytes, and could facilitate the development of liver disease.
Copyright © 2013 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcoholic Hepatitis; CD4+ CD25hi CD127−/lo Tregs; Chronic Alcoholism; Inflammatory Cytokines

Mesh:

Substances:

Year:  2013        PMID: 23550693     DOI: 10.1111/acer.12095

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  15 in total

1.  Peripheral blood CD4+/CD25+ regulatory T cells in alcoholic patients with Strongyloides stercoralis infection.

Authors:  Steveen Rios Ribeiro; Luciana Polaco Covre; Lorenzzo Lyrio Stringari; Maria da Penha Zago-Gomes; Daniel Cláudio Oliveira Gomes; Fausto Edmundo Lima Pereira
Journal:  Parasitol Res       Date:  2017-01-12       Impact factor: 2.289

Review 2.  Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes.

Authors:  Laura E Nagy; Wen-Xing Ding; Gail Cresci; Paramananda Saikia; Vijay H Shah
Journal:  Gastroenterology       Date:  2016-02-23       Impact factor: 22.682

Review 3.  The detection and role of heat shock protein 70 in various nondisease conditions and disease conditions: a literature review.

Authors:  Baoge Qu; Yiguo Jia; Yuanxun Liu; Hui Wang; Guangying Ren; Hong Wang
Journal:  Cell Stress Chaperones       Date:  2015-07-03       Impact factor: 3.667

4.  Regulatory T cells suppress excessive lipid accumulation in alcoholic liver disease.

Authors:  Hongwu Wang; Ting Wu; Yaqi Wang; Xiaoyang Wan; Junying Qi; Lan Li; Xiaojing Wang; Xiaoping Luo; Qin Ning
Journal:  J Lipid Res       Date:  2019-02-21       Impact factor: 5.922

5.  Pharmacological Inhibition of CCR2/5 Signaling Prevents and Reverses Alcohol-Induced Liver Damage, Steatosis, and Inflammation in Mice.

Authors:  Aditya Ambade; Patrick Lowe; Karen Kodys; Donna Catalano; Benedek Gyongyosi; Yeonhee Cho; Arvin Iracheta-Vellve; Adeyinka Adejumo; Banishree Saha; Charles Calenda; Jeeval Mehta; Eric Lefebvre; Pamela Vig; Gyongyi Szabo
Journal:  Hepatology       Date:  2019-02-12       Impact factor: 17.425

6.  T regulatory cells and dendritic cells protect against transfusion-related acute lung injury via IL-10.

Authors:  Rick Kapur; Michael Kim; Rukhsana Aslam; Mark J McVey; Arata Tabuchi; Alice Luo; Jonathan Liu; Yuan Li; Shanjeevan Shanmugabhavananthan; Edwin R Speck; Anne Zufferey; George Yousef; Haibo Zhang; Matthew T Rondina; Andrew S Weyrich; Leendert Porcelijn; Wolfgang M Kuebler; Arthur S Slutsky; John W Semple
Journal:  Blood       Date:  2017-02-15       Impact factor: 22.113

Review 7.  Biomarkers of alcohol misuse: recent advances and future prospects.

Authors:  Iwona Jastrzębska; Agnieszka Zwolak; Michał Szczyrek; Agnieszka Wawryniuk; Barbara Skrzydło-Radomańska; Jadwiga Daniluk
Journal:  Prz Gastroenterol       Date:  2016-06-08

8.  Changes in tumor necrosis factor-α, heat shock protein 70, malondialdehyde, and superoxide dismutase in patients with different severities of alcoholic fatty liver disease: a prospective observational study.

Authors:  Bao-Ge Qu; Hui Wang; Yi-Guo Jia; Ji-Liang Su; Zhong-Dong Wang; Ya-Fei Wang; Xing-Hai Han; Yuan-Xun Liu; Jin-Dun Pan; Guang-Ying Ren
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

Review 9.  Alcoholic Liver Disease: Role of Cytokines.

Authors:  Manuela G Neuman; Yaakov Maor; Radu M Nanau; Ehud Melzer; Haim Mell; Mihai Opris; Lawrence Cohen; Stephen Malnick
Journal:  Biomolecules       Date:  2015-08-28

Review 10.  Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives.

Authors:  Hannah C Jeffery; Manjit Kaur Braitch; Solomon Brown; Ye Htun Oo
Journal:  Front Immunol       Date:  2016-09-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.